DAVID W. ORTBALS, M.D.; HARVEY LIEBHABER, M.D.; CARY A. PRESANT, M.D., F.A.C.P.; ALBERT L. VAN AMBURG III, M.D.; JEANETTE Y. LEE, Ph.D.
To characterize the immunogenicity of influenza vaccine in patients with malignant disease, 21 patients with lymphoreticular neoplasms and 21 patients with solid tumors were immunized with inactivated influenza A/New Jersey/76 whole virus vaccine. The patients were randomized with respect to time of vaccine administration in relation to administration of chemotherapy. Fourfold or greater antibody titer increases occurred in 94% of controls and 71% of cancer patients (P < 0.05), and the magnitude of antibody response was also significantly lower in cancer patients (P < 0.01). There was no correlation of antibody responsiveness with sex, age, tumor type, absolute lymphocyte count, disease status, or type of chemotherapeutic agent used. Fifty percent of patients immunized at the time of chemotherapy administration showed seroconversion, which is significantly less than the 93% response rate observed in patients immunized between chemotherapy courses. It is thus recommended that individuals with malignant disease should receive influenza immunization between chemotherapy courses.
ORTBALS DW, LIEBHABER H, PRESANT CA, et al. Influenza Immunization of Adult Patients with Malignant Diseases. Ann Intern Med. 1977;87:552–557. doi: 10.7326/0003-4819-87-5-552
Download citation file:
Published: Ann Intern Med. 1977;87(5):552-557.
Hematology/Oncology, Infectious Disease, Influenza, Prevention/Screening, Vaccines/Immunization.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use